ApoE genotyping and response to galanthamine in Alzheimer's disease - A real life retrospective study

Collegium Antropologicum

Volumn 28, Issue 1, 2004, Pages 199-204

  Babić, Tomislav ^a   Lakušić, Darija Mahović ^a   Sertić, Jadranka ^b   Petrovečki, Mladen ^c   Stavljenić Rukavina, Ana ^b  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c University of Zagreb School of Medicine   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; GALANTAMINE;

ADULT; AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CHOLINESTERASE INHIBITORS; FEMALE; GALANTAMINE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES;

EID: 3142523591     PISSN: 03506134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. DAVIES, P., A. J. MALONEY, Lancet, 2 (1976) 1403.
2. IQBAL, K., H. M. WISNIEWSKI, B. WINDBLAD: Alzheimer's disease and related disorders. (Alan R Liss Inc., New York, 1989).
3. HARVEY, A. L., Pharmac. Ther., 68 (1995) 113.
4. SWEENEY, J. E., C. F. HOHMANN, T. H. MORAN, J. T. COYLE, Pharmacology and Behaviour, 31 (1988) 141.
5. DAL-BIANCO, P., J. MALY, C. WOBER, C. LIND, G. KOCH, J. HUFGARD, I. MARSCHALL, M. MRAZ, L. DEECKE, Neural. Transm., 33 Suppl. (1991) 59.
6. FULTON, B., P. BENFIELD, Drugs Aging, 9 (1996) 60.
7. POIRIER, J., J. DAVIGNON, D. BOUTHILLIER, S. KOGAN, P. BERTRAND, S. GAUTHIER, Lancet, 342 (1993) 697.
8. POIRIER, J., M. C. DELISLE, R. QUIRION, I. AUBERTT, M. FARLOW, D. LAHIRI, S. HUI, P. BERTRAND, J. NALBANTOGLU, B. M. GILFIX, Proc. Natl. Acad. Sci. USA, 92 (1995) 12260.
9. MCKAHN, G., D. DRACHMAN, M. FOLSTEIN, R. KATZMAN, D. PRICE, E. M. STADLAN, Neurology, 34 (1984) 939.
10. FOLSTEIN, M., S. FOLSTEIN, P. MCHUGH, J. Psych. Res., 12 (1975) 189.
11. HIXON, J. E., D. T. WERNIER, J. Lipid. Res., 31 (1990) 545.
12. THOMSEN, T., B. KADEN, J. P. FISCHER, U. BICKEL, H. BARZ, G. GUSZTONY, J. CERVOS-NAVARRO, H. KEWITZ, Eur. J. Clin. Chem. Clin. Biochem., 29 (1991) 487.
13. PEREIRA, E. F.,M. ALKONDON, S. REINHARDT, A. MAELICKE, X. PENG, J. LINDSTRO, P. WHITING, E. X. ALBUQUERQUE, J. Pharmacol. Exp. Ther., 270 (1994) 768.
14. COZANTIS, D., A. DESSYPRIS, K. NUUTILA, Acta Aneast. Scand., 28 (1980) 166.
15. DAVIS, K. L., L. J. THAL, E. R. GAMZU, N. Engl. J. Med., 327 (1992) 1253.
16. ROGERS, S. L., M. R. FARLOW, R. S. DOODY, R. MOHS, L. T. FRIEDHOFF, Neurology, 50 (1998) 136.
17. COREY-BLOOM, J., R. ANAND, Int. J. Geriatr. Psychopharmacol., 1 (1998) 55.
18. LARNER, A. J., S. F. FARMER, BMJ, 319 (1999) 362.
19. COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP), (The European Agency for the Evaluation of Medicinal Products, London, 1997).
20. ROSEN, W. G., R. C. MOHS, K. L. DAVIS, Am. J. Psych., 14 (1984) 1356.
21. LEBER, P., (Food and Drug Administration, Centre for Drug Evaluation and Research, Office of Drug Evaluation, Division of Neuropharmacologic Products, Rockville, 1990).